Meyer G, Emmerich J, Helley D, Arnaud E, Nicaud V, Alhenc-Gelas M, Aiach M, Fischer A, Sors H, Fiessinger J N
Service de Pneumologie-réanimation (GM, HS), Hôpital Laennec, Université Paris V, Paris, France.
Am J Med. 2001 Jan;110(1):12-5. doi: 10.1016/s0002-9343(00)00653-7.
Factor V Leiden and factor II 20210A are inherited disorders of the clotting system that occur frequently in patients with deep vein thrombosis. We conducted this study to determine whether these factors are also common in patients with pulmonary embolism.
We determined the prevalence of factor V Leiden and factor II 20210A in 773 consecutive patients with objectively documented symptomatic deep vein thrombosis or symptomatic pulmonary embolism, or with a combination of these disorders.
Isolated symptomatic deep vein thrombosis occurred in 345 patients; isolated symptomatic pulmonary embolism occurred in 236; and both anomalies occurred in 192. Factor V Leiden was present in 21 (9%) of the patients with isolated symptomatic pulmonary embolism, in 30 (16%) with both manifestations, and in 63 (18%) with isolated symptomatic deep vein thrombosis (P = 0.007). Factor V Leiden was more common among patients with deep vein thrombosis (odds ratio [OR] = 2.1; 95% confidence interval [CI]: 1.2 to 3.7; P = 0.006) or both pulmonary embolism and deep vein thrombosis (OR = 1.8; 95% CI: 1.0 to 3.3; P = 0.07) than among patients with isolated pulmonary embolism. Factor V Leiden was less common in massive pulmonary embolism (5% [7 of 127]) than in submassive pulmonary embolism (13% [21 of 155], P = 0.03). We found no significant difference in the prevalence of factor II 20210A among the three groups.
Factors V Leiden and II 20210A vary in prevalence among patients with pulmonary embolism and deep vein thrombosis, suggesting that the risk of pulmonary embolization may vary among patients who have different causes of venous thromboses.
凝血因子V莱顿突变(Factor V Leiden)和凝血因子II 20210A突变是凝血系统的遗传性疾病,在深静脉血栓形成患者中经常出现。我们开展这项研究以确定这些因素在肺栓塞患者中是否也很常见。
我们确定了773例连续的、有客观记录的有症状的深静脉血栓形成或有症状的肺栓塞患者,或同时患有这两种疾病的患者中凝血因子V莱顿突变和凝血因子II 20210A突变的患病率。
345例患者出现孤立性有症状的深静脉血栓形成;236例出现孤立性有症状的肺栓塞;192例同时出现这两种异常情况。在孤立性有症状的肺栓塞患者中,21例(9%)存在凝血因子V莱顿突变;在同时出现两种表现的患者中,30例(16%)存在该突变;在孤立性有症状的深静脉血栓形成患者中,63例(18%)存在该突变(P = 0.007)。凝血因子V莱顿突变在深静脉血栓形成患者(优势比[OR]=2.1;95%置信区间[CI]:1.2至3.7;P = 0.006)或同时患有肺栓塞和深静脉血栓形成的患者(OR = 1.8;95% CI:1.0至3.3;P = 0.07)中比在孤立性肺栓塞患者中更常见。凝血因子V莱顿突变在大面积肺栓塞患者中(5%[127例中的7例])比在次大面积肺栓塞患者中(13%[155例中的21例])少见,P = 0.03。我们发现三组患者中凝血因子II 20210A突变的患病率没有显著差异。
凝血因子V莱顿突变和凝血因子II 20210A突变在肺栓塞和深静脉血栓形成患者中的患病率不同,这表明在有不同静脉血栓形成原因的患者中,肺栓塞的风险可能有所不同。